Squarepoint
GNMX

Squarepoint’s Aevi Genomic Medicine Inc GNMX Stock Holding History

Squarepoint’s Portfolio GNMX Stock Details GNMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-10,500
Closed -$13K – 2451
2017
Q3 		$13K Sell
10,500
-13,789
-57% -$17.6K ﹤0.01% 1581
2017
Q2 		$32K Buy
+24,289
New +$35.1K ﹤0.01% 1476
2017
Q1 		– Sell
-31,152
Closed -$161K – 2091
2016
Q4 		$161K Buy
+31,152
New +$164K 0.01% 1519

Other funds holding GNMX

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return

Squarepoint's GNMX Position: Q4 2017 in Review

Squarepoint sold out of Aevi Genomic Medicine Inc (GNMX) in Q4 2017, closing a stake of 10,500 shares — an estimated $13K sold.

Squarepoint first reported a position in GNMX in Q4 2016 and held it in 3 quarters. The position peaked at $161K in Q4 2016. 45 funds tracked by Wall St. Rank hold GNMX as of Q4 2017.

  • Squarepoint reported no remaining Aevi Genomic Medicine Inc position as of Q4 2017 after selling out during the quarter.
  • Squarepoint sold 10,500 Aevi Genomic Medicine Inc shares in Q4 2017, an estimated $13K.
  • Squarepoint first reported a position in Aevi Genomic Medicine Inc in Q4 2016 and held it in 3 quarters.
  • Squarepoint's Aevi Genomic Medicine Inc position peaked at $161K in Q4 2016.
  • 45 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q4 2017.

Based on Squarepoint's 13F filing for Q4 2017, filed 14 Feb 2018.